Integrated HEOR, market access, policy and global health expertise.
Five practices covering the evidence, the access strategy, the policy case and the message, for life sciences companies, governments and global health organisations.




Health economics and evidence
Cost-effectiveness and budget impact modelling, systematic reviews, indirect treatment comparisons, statistics and real-world evidence.

Market access and HTA
NICE, SMC, AWMSG, NCPE and CDA-AMC submissions, EU JCA dossiers, pricing and reimbursement strategy, value communication and policy.

Strategic advisory
Advisory boards, portfolio and indication prioritisation, early HTA advice, access due diligence for investors and in-house training.

Policy, communications and advocacy
Health policy analysis, public affairs, health communications, advocacy and campaigns for companies, NGOs, governments and patient groups.

Global health and policy
Situation analysis, MEAL, programme costing, return on investment, advocacy and campaigns for NGOs, INGOs, donors and governments.
Where each practice comes in.
- 01Early development
- 02Phase II–III
- 03HTA submission
- 04Pricing and negotiation
- 05Launch and life cycle
Clients across life sciences, global health and the third sector.
Pharma and biotech, emerging to global
HTA submissions, JCA dossiers, value dossiers and launch strategy.
MedTech and diagnostics
Early value assessment, evidence plans and economic models for HTA and procurement.
HealthTech and digital health
Value demonstration and NHS business cases for payers and health systems.
HEOR, market access and communication agencies
White-label modelling, reviews and writing, with senior capacity when deadlines tighten.
Investors
Access due diligence, market sizing and pricing benchmarks for deal decisions.
Global health, NGOs, INGOs and charities
Situation analysis, programme costing, MEAL, return on investment and the case for funders.
Academia and research institutions
Research partnerships, methods support and grant work.
Patient advocacy groups
Evidence for HTA patient input, policy advocacy and public awareness campaigns.
What does Evidaxia do?
Evidaxia is an independent health economics, market access and global health consultancy. We build economic models and evidence packages, prepare HTA and EU JCA submissions, support pricing and reimbursement, and help NGOs, charities and public health programmes measure and communicate their impact.
How is Evidaxia different?
Our founder worked inside NICE as an HTA Technical Lead and Analyst, so we build evidence the way assessors read it. The senior person who scopes your project does the work, from the first model to the final meeting.
Do you support HTA submissions and the EU JCA?
Yes. We support NICE, SMC, AWMSG, NCPE, CDA-AMC and EU JCA work, from early advice and PICO scoping to the dossier, clarification questions, resubmission and price negotiation.
Which therapy areas and technologies do you cover?
Our work spans oncology, rare diseases, cell and gene therapy, cardiovascular, ophthalmology, respiratory, haematology and women's health, for medicines, advanced therapies, devices, diagnostics and digital health.
Do you work with NGOs, charities and global health organisations?
Yes. We help them with situation analysis, MEAL, costing, return on investment, advocacy and campaigns. We also take on pro bono partnerships with selected community organisations, charities and patient groups.
How do engagements work?
Every project starts with a free, no-obligation 30-minute call about the decision ahead. We then agree the scope, deliverables and timelines before work starts, and the senior consultant who scopes the work delivers it.
Do you provide health communications, policy and advocacy support?
Yes. We provide policy analysis and benchmarking, stakeholder mapping, public affairs, policy briefs and consultation responses, health communications, media relations and advocacy campaigns, for companies, NGOs, governments and patient groups.
Where are you based?
We are based in the EU and work across the UK, Ireland, Europe, Canada and the US, and with global health programmes in low- and middle-income countries.
Specialist services
NICE, SMC and AWMSG submissions
Evidence submissions, models and committee preparation for England, Scotland and Wales.
Learn moreNCPE submissions in Ireland
Rapid review and full HTA submissions, built to HIQA methods.
Learn moreHealth economic modelling
Cost-effectiveness and budget impact models that hold up.
Learn moreNMA and indirect comparisons
NMA, MAIC, STC and ML-NMR to NICE DSU and JCA guidance.
Learn moreValue dossiers
GVDs, value stories and payer question-and-answer guides, tested with payers.
Learn moreSLR updates and living reviews
Updates and living reviews, including reviews built by others.
Learn moreNeed support with value demonstration or market access?
Start with a free, no-obligation 30-minute call with a senior consultant.